• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

预防肝硬化腹水穿刺引起的循环功能障碍:标准剂量与半剂量白蛋白。一项前瞻性、随机、非盲的初步研究。

Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: standard vs half albumin doses. A prospective, randomized, unblinded pilot study.

机构信息

Division of Gastroenterology and Hepatology, San Giovanni Battista Hospital - University of Turin, Turin, Italy.

出版信息

Dig Liver Dis. 2011 Nov;43(11):881-6. doi: 10.1016/j.dld.2011.06.001. Epub 2011 Jul 8.

DOI:10.1016/j.dld.2011.06.001
PMID:21741331
Abstract

BACKGROUND

Paracentesis-induced circulatory dysfunction is a well-known complication of large volume paracentesis. Albumin infusion (8g of albumin/L of ascites removed) is effective in preventing it, but high costs and scant availability limit its use.

AIM

To compare standard vs half albumin doses.

METHODS

Seventy cirrhotic patients treated with large volume paracentesis were randomized to receive intravenous albumin as prevention of paracentesis-induced circulatory dysfunction: group 1 (35 patients) received 4g/L of ascites removed, group 2 (35 patients) received 8g/L of ascites removed.

RESULTS

The incidence of paracentesis-induced circulatory dysfunction (14% vs 20% in group 1 and group 2, respectively; p=ns), hyponatremia (9% vs 6%, p=ns) and renal impairment (0% in both groups) on the 6th day from paracentesis was similar between the two groups. After 6 months of follow-up, rates of survival and of recurrence of ascites requiring large volume paracentesis were not different between the two groups.

CONCLUSIONS

This unblinded, randomized, pilot study suggests that treatment with half doses of albumin is effective in the prevention of paracentesis-induced circulatory dysfunction and its related clinical complications in cirrhotic patients with tense ascites treated by large volume paracentesis. If confirmed, these results could support a significant costs reduction in the management of ascites in cirrhotic patients.

摘要

背景

大量放腹水可引起循环功能障碍,是一种已知的并发症。输注白蛋白(每升腹水移除 8g 白蛋白)可有效预防,但费用高且供应有限,限制了其应用。

目的

比较标准剂量与半剂量白蛋白。

方法

70 例肝硬化大量放腹水患者随机分为两组,静脉输注白蛋白预防放腹水引起的循环功能障碍:第 1 组(35 例)接受每升腹水移除 4g 白蛋白,第 2 组(35 例)接受每升腹水移除 8g 白蛋白。

结果

两组第 6 天放腹水后循环功能障碍(第 1 组 14%,第 2 组 20%;p=ns)、低钠血症(第 1 组 9%,第 2 组 6%;p=ns)和肾功能损害(两组均为 0%)的发生率相似。随访 6 个月,两组的生存率和需要大量放腹水治疗的复发性腹水率无差异。

结论

这项非盲、随机、初步研究表明,对于大量放腹水治疗的张力性腹水肝硬化患者,用半剂量白蛋白治疗可有效预防放腹水引起的循环功能障碍及其相关临床并发症。如果得到证实,这些结果可能会降低肝硬化腹水患者管理的成本。

相似文献

1
Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: standard vs half albumin doses. A prospective, randomized, unblinded pilot study.预防肝硬化腹水穿刺引起的循环功能障碍:标准剂量与半剂量白蛋白。一项前瞻性、随机、非盲的初步研究。
Dig Liver Dis. 2011 Nov;43(11):881-6. doi: 10.1016/j.dld.2011.06.001. Epub 2011 Jul 8.
2
Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites.比较白蛋白和生理盐水预防肝硬化腹水患者穿刺放腹水引起的循环功能障碍的随机试验。
Hepatology. 2003 May;37(5):1147-53. doi: 10.1053/jhep.2003.50169.
3
Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study.预防腹腔穿刺术引起的循环功能障碍:米多君与白蛋白对比。一项随机试点研究。
Liver Int. 2008 Aug;28(7):1019-25. doi: 10.1111/j.1478-3231.2008.01734.x. Epub 2008 Apr 11.
4
Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study.特利加压素与白蛋白治疗肝硬化腹腔穿刺术诱发循环功能障碍的随机对照研究
J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 2):303-7. doi: 10.1111/j.1440-1746.2006.04182.x.
5
Noradrenaline and albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized pilot study.去甲肾上腺素和白蛋白在肝硬化穿刺放腹水诱发循环功能障碍中的作用:一项随机试点研究
J Intern Med. 2006 Jul;260(1):62-8. doi: 10.1111/j.1365-2796.2006.01654.x.
6
Comparison of midodrine and albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients: a randomized pilot study.米多君与白蛋白预防肝硬化患者腹水穿刺诱导性循环功能障碍的比较:一项随机初步研究。
J Clin Gastroenterol. 2014 Feb;48(2):184-8. doi: 10.1097/MCG.0b013e31829ae376.
7
Albumin May Prevent the Morbidity of Paracentesis-Induced Circulatory Dysfunction in Cirrhosis and Refractory Ascites: A Pilot Study.白蛋白可能预防肝硬化和顽固性腹水患者腹腔穿刺术诱发的循环功能障碍的发病:一项初步研究。
Dig Dis Sci. 2016 Oct;61(10):3084-3092. doi: 10.1007/s10620-016-4140-3. Epub 2016 Apr 5.
8
Treatment of cirrhotic tense ascites with Dextran-40 versus albumin associated with large volume paracentesis: a randomized controlled trial.右旋糖酐40与白蛋白联合大量腹腔穿刺术治疗肝硬化张力性腹水:一项随机对照试验
Ann Hepatol. 2002 Jan-Mar;1(1):29-35.
9
[Treatment of ascites in patients with liver cirrhosis without neither hyponatremia nor renal insufficiency. Results of a randomized study comparing diuretics and punctures compensated by albumin].[肝硬化无低钠血症及肾功能不全患者腹水的治疗。比较利尿剂与白蛋白补偿穿刺术的随机研究结果]
Gastroenterol Clin Biol. 1992;16(10):751-5.
10
Cardiovascular, renal, and neurohumoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites.肝硬化伴利尿剂抵抗性腹水患者对单次大量腹腔穿刺放液的心血管、肾脏及神经体液反应
Am J Gastroenterol. 1997 Mar;92(3):394-9.

引用本文的文献

1
Controversies regarding albumin therapy in cirrhosis.关于肝硬化患者白蛋白治疗的争议。
Hepatology. 2025 Jan 1;81(1):288-303. doi: 10.1097/HEP.0000000000000521. Epub 2023 Aug 7.
2
Review article: Practical considerations for fluid resuscitation in cirrhosis.综述文章:肝硬化液体复苏的实用考虑。
Aliment Pharmacol Ther. 2023 May;57(10):1066-1082. doi: 10.1111/apt.17458. Epub 2023 Mar 30.
3
The Management of Postoperative Cognitive Dysfunction in Cirrhotic Patients: An Overview of the Literature.肝硬化患者术后认知功能障碍的管理:文献综述。
Medicina (Kaunas). 2023 Feb 26;59(3):465. doi: 10.3390/medicina59030465.
4
Large volume paracentesis of 39.5 liters chylous ascites in the setting of high-grade follicular lymphoma.在高级别滤泡性淋巴瘤背景下进行39.5升乳糜性腹水的大量腹腔穿刺术。
Radiol Case Rep. 2022 Sep 13;17(11):4276-4279. doi: 10.1016/j.radcr.2022.08.036. eCollection 2022 Nov.
5
Management of refractory ascites.难治性腹水的处理。
Clin Mol Hepatol. 2023 Jan;29(1):16-32. doi: 10.3350/cmh.2022.0104. Epub 2022 Jun 9.
6
Management of Ascites in Patients with Cirrhosis: An Update.肝硬化患者腹水的管理:最新进展
J Clin Med. 2021 Nov 10;10(22):5226. doi: 10.3390/jcm10225226.
7
Albumin Administration is Efficacious in the Management of Patients with Cirrhosis: A Systematic Review of the Literature.白蛋白给药对肝硬化患者的治疗有效:文献系统评价
Hepat Med. 2020 Oct 27;12:153-172. doi: 10.2147/HMER.S264231. eCollection 2020.
8
Guidelines on the management of ascites in cirrhosis.肝硬化腹水管理指南。
Gut. 2021 Jan;70(1):9-29. doi: 10.1136/gutjnl-2020-321790. Epub 2020 Oct 16.
9
HEP-Net opinion on the management of ascites and its complications in the setting of decompensated cirrhosis in the resource constrained environment of Pakistan.HEP-Net关于在巴基斯坦资源有限环境下失代偿期肝硬化患者腹水及其并发症管理的意见。
Pak J Med Sci. 2020 Jul-Aug;36(5):1117-1132. doi: 10.12669/pjms.36.5.2407.
10
Pathophysiology and Prevention of Paracentesis-induced Circulatory Dysfunction: A Concise Review.腹腔穿刺术诱发循环功能障碍的病理生理学与预防:简要综述
J Clin Transl Hepatol. 2020 Mar 28;8(1):42-48. doi: 10.14218/JCTH.2019.00048. Epub 2020 Mar 26.